IdiomacatalàDeutschEnglishespañoleuskarafrançaisgalegoitalianoportuguêsromână
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Javier Solera
La canción de Navidad
IdiomacatalàDeutschEnglishespañoleuskarafrançaisgalegoitalianoportuguêsromână
Portfolio IV
IdiomacatalàDeutschEnglishespañoleuskarafrançaisgalegoitalianoportuguêsromână
Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab-cilgavimab
Monoclonal antibodies against SARS-CoV-2 have been useful prophylactic and therapeutic tools in patients at high risk of severe COVID-19. However, the use of this approach depends on the SARS-CoV-2 variant. 1 Levin MJ Ustianowski A De Wit S et al. Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of COVID-19.
Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave
2.7 Impact of early outpatient remdesivir A total of 86 patients (44.8%) received remdesivir as an outpatient within 7 days of symptom onset. Most received 3 doses of the intravenous antiviral, with only 2 patients that received 1 dose. Hospitalization occurred in 2/86 (2.3%) patients that received outpatient remdesivir and 13/106 (12.3%) of those that did not, p = .013.
Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave
ABSTRACT Solid organ transplant recipients (SOTr) remain at risk of severe COVID-19. Several previous early therapies are no longer effective against new circulating variants. We performed a prospective cohort study in outpatient adult SOTr during the omicron BA.2 wave (April–May 2022), to determine the effectiveness of 3 doses of remdesivir given within 7 days of symptoms onset. Patients were followed for at least 30 days. The primary outcome was hospitalization.
Short‐course Early Outpatient Remdesivir Prevents Severe Disease due to COVID‐19 in Organ Transplant Recipients During the Omicron BA.2 Wave
ORIGINAL ARTICLE This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1111/ajt.17199 Abstract Solid organ transplant recipients (SOTr) remain at risk of severe COVID-19. Several previous early therapies are no longer effective against new circulating variants.
Severity of COVID-19 among solid organ transplant recipients in Canada, 2020-2021: a prospective, multicentre cohort study
Disease severity Patient characteristics that were significantly associated with need for supplemental oxygen and hospital admission on univariate analysis are reported in Table 1 and Appendix 1, Supplementary Table 2, respectively. On multivariable analysis (Table 2), factors associated with need for supplemental oxygen were age, number of comorbidities, higher tacrolimus level and lower lymphocyte count.
Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings - Nature Communications
Abstract Immunocompromised patients are predisposed to severe COVID-19. Here we compare homotypic and heterotypic humoral and cellular immune responses to Omicron BA.1 in organ transplant patients across a diverse clinical spectrum. We perform variant-specific pseudovirus neutralization assays for D614G, and Omicron-BA.1, -BA.2, and Delta variants. We also measure poly-and monofunctional T-cell responses to BA.1 and ancestral SARS-CoV-2 peptide pools.
Proof of Concept: SAPUI5 application using AWS SNS service
Today, the use of cloud services is necessary, since it is the logical path to the evolution of IT systems. Each cloud provider offers a series of services and we, as developers, have to know how to use/integrate these services. Using different services from different cloud providers, we can provide a complete solution to business without any limitations. This blog post explains a proof of concept that how to use AWS SNS in SAPUI5 application.
Treatment of pulmonary brucellosis: a systematic review
Introduction: Pulmonary involvement is a rare, focal complication of human brucellosis. The aim of this review is to describe clinical and radiologic features, treatment administered and clinical course of these patients. Areas covered: We conducted a systematic search of scientific reports of brucellosis with pulmonary involvement published from January 1985 to July 2016. Four main patterns of disease were observed: pneumonia, pleural effusion, nodules and interstitial pattern.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Javier
Contact Javier, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack